Low-dose CBD extract unexpectedly improved social behavior and anxiety in a 15-year-old with autism

A 15-year-old boy with autism, selective mutism, anxiety, and controlled epilepsy was prescribed CBD-based extract to potentially replace seizure medications. At a lower dose than typically reported for autism, he showed unanticipated improvements in behavioral symptoms, core social communication abilities, anxiety, sleep, and weight control. The social improvements were notable because they addressed core autism deficits, not just associated behaviors.

Single case report documenting response to pharmaceutical-grade CBD-based extract in a 15-year-old with comorbid autism spectrum disorder, selective mutism, anxiety, and epilepsy.

Current autism medications target associated symptoms (irritability, anxiety) but not the core social communication deficits. This case is notable because social improvements were observed at a dose lower than expected, suggesting a potential therapeutic window.

The endocannabinoid system is increasingly implicated in social behavior. This case adds to a small but growing literature suggesting cannabinoids may address the core social deficits of autism, not just comorbid symptoms.

Single case report (cannot generalize); multiple comorbidities confound attribution; placebo effects possible; no standardized outcome measures described; dose specifics not fully detailed in abstract; prior epilepsy medication changes could contribute.